MedWatch

Pharmacosmos' revenue grows by USD 16m despite corona challenges

Investments in the US and China have affected Pharmacosmos' bottom line, but the company has increased its revenue and expects growth to continue in the new financial year.

Photo: Pharmacosmos / PR

In a previous accounting report, Pharmacosmos warned that it would probably end the year with a deficit on the bottom line, its first in 15 years -- and this prediction came true.

The company has ended its 2020/2021 financial year with a total deficit of USD 19.7m, a contrast to the USD 8m profit the company reported in its last accounting year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs